Los Angeles-based Cedars-Sinai has launched Coronet Ventures Netherlands, a venture fund focused on early-stage health and life sciences startups that plans to invest $50 million in the next decade.
The new fund marks Cedars-Sinai’s third international investment initiative and aims to support Dutch companies developing technologies for the U.S. healthcare market. It will operate under Cedars-Sinai Technology Ventures and is the health system’s third international venture fund.
Coronet Ventures Netherlands will provide startups with access to Cedars-Sinai’s clinical data, pilot programs and product validation. In return, the health system will gain early access to emerging technologies.
“This partnership allows us to create a platform with underlying capital that also offers deep clinical validation and commercialization support to help healthcare and biotechnology companies scale more quickly into the U.S.,” said Nirdesh K. Gupta, PhD, managing partner of Cedars-Sinai Intellectual Property Company.
The fund builds on a four-year collaboration between Cedars-Sinai and Dutch innovators. Two Netherlands-based companies — HealthPlus.ai and Syntho — have already participated in the Cedars-Sinai Accelerator, with Syntho completing a pilot program and entering talks with the system’s artificial intelligence lab.
